` HBIO (Harvard Bioscience Inc) vs S&P 500 Comparison - Alpha Spread

HBIO
vs
S&P 500

Over the past 12 months, HBIO has underperformed S&P 500, delivering a return of -64% compared to the S&P 500's +14% growth.

Stocks Performance
HBIO vs S&P 500

Loading
HBIO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HBIO vs S&P 500

Performance Gap Between HBIO and GSPC
HIDDEN
Show

Performance By Year
HBIO vs S&P 500

Loading
HBIO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Harvard Bioscience Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Harvard Bioscience Inc
Glance View

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 475 full-time employees. The company went IPO on 2013-10-21. The firm provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms or preclinical, and clinical. The firm organizes its product line activities into two product families, Cellular and Molecular Technologies (CMT) and Preclinical. The company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The firm's customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

HBIO Intrinsic Value
HIDDEN
Show
Back to Top